About
Polyneuron Pharmaceuticals AG develops injectable glycopolymer drugs using its Antibody-Catch™ platform to selectively eliminate pathogenic autoantibodies involved in antibody-mediated autoimmune diseases, with a focus on peripheral neuropathies like anti-MAG neuropathy.
Explore Polyneuron Pharmaceuticals AG's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.